Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  • Mary V Relling
  • Matthias Schwab
  • Michelle Whirl-Carrillo
  • Guilherme Suarez-Kurtz
  • Ching-Hon Pui
  • Charles M Stein
  • Ann M Moyer
  • William E Evans
  • Teri E Klein
  • Federico Guillermo Antillon-Klussmann
  • Kelly E Caudle
  • Motohiro Kato
  • Allen E J Yeoh
  • Kjeld Schmiegelow
  • Jun J Yang
Vis graf over relationer

Thiopurine methyltransferase (TPMT) activity exhibits a monogenic codominant inheritance and catabolizes thiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines. Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduce the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression. We provide recommendations for adjusting starting doses of azathioprine, mercaptopurine, and thioguanine based on TPMT and NUDT15 genotypes (updates on www.cpicpgx.org).

OriginalsprogEngelsk
TidsskriftClinical Pharmacology and Therapeutics
Vol/bind105
Udgave nummer5
Sider (fra-til)1095-1105
Antal sider11
ISSN0009-9236
DOI
StatusUdgivet - 2019

Bibliografisk note

© 2018 The Authors Clinical Pharmacology & Therapeutics © 2018 American Society for Clinical Pharmacology and Therapeutics.

ID: 59083943